Quote
—
—
No scored catalysts in the window yet.
Market cap
—
P/E
—
EPS
—
Beta
—
52W range
—
Day range
—
Open
—
Prev close
—
Volume
—
Avg volume
—
Dividend
—
IPO
—
https://www.prnewswire.com/news-releases/hansa-biopharma-announces-first-commercial-kidney-transplant-patient-treated-with-idefirix-in-australia-302853712.html · 8/18/2026+0.80
https://www.prnewswire.com/news-releases/hansa-biopharma-reports-positive-efficacy-and-safety-results-from-idefirix-european-post-authorization-study-in-kidney-transplantation-302782744.html · 5/27/2026+1.00
https://www.prnewswire.com/news-releases/hansa-biopharma-announces-late-breaking-abstract-from-confides-phase-3-trial-selected-for-oral-presentation-at-atc-2026-302781429.html · 5/26/2026+0.80
https://www.prnewswire.com/news-releases/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026-302704610.html · 3/4/2026+0.60
https://www.prnewswire.com/news-releases/pdufa-action-date-for-hansa-biopharmas-imlifidase-bla-set-for-december-19-2026-302704609.html · 3/4/2026+0.60
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
